Results 91 to 100 of about 213,637 (257)

Lactate‐H3K18la‐RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair

Advanced Science, EarlyView.
A lactate‐H3K18la epigenetic axis upregulates RPL11 to drive gemcitabine resistance in pancreatic cancer. RPL11 orchestrates chemoresistance through a dual, compartmentalized role: enhancing cytoplasmic protein synthesis via EEF1A1 stabilization and promoting nuclear DNA damage repair by co‐activating PARP14, thus ensuring robust cell survival ...
Lijun Zhao, Jianzhong Cao, Wenyue Liu, Xuyun Li, Haolin Zhang, Xiaofang Zhang, Shiyang Shi, Huilong Yin, Junjie Li, Angang Yang, Rui Zhang   +10 more
wiley   +1 more source

Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53

, 2019
Spindle poisons elicit various cellular responses following metaphase arrest, but how they relate to long-term clonogenicity has remained unclear. We prepared several HeLa lines in which the canonical apoptosis pathway was attenuated, and compared their ...
Shinji Yasuhira (2591341), Chihaya Maesawa (144541), Masahiko Shibazaki (2591332), Masao Nishiya (3229377)   +3 more
core   +1 more source

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan, Shulei Sun, Ran Hu, Yuheng Feng, Xinhao Wu, Fangqi Liu, Xuyong Lin, Xiupeng Zhang, Xuezhu Rong, Qiang Han   +9 more
wiley   +1 more source

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Bangladesh Journal of Pharmacology, 2015
We investigated dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment on stage II-IV ovarian cancer patients.
Zhenhua Du, Xiaolin Ma
doaj  

Table_3_nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.docx

, 2018
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC).
Matei P. Socoteanu (5546894), Teng J. Ong (5546897), Manuel Modiano (5546885), Kartik Konduri (5546879), Eric C. Anderson (3073926), Jonathan W. Goldman (5546906), on behalf of the ABOUND.70+ Investigators (5546903), Daniel E. Haggstrom (5546888), Edward S. Kim (2183847), Corey J. Langer (5546882), Robert M. Jotte (5546891), Tymara Berry (5546843), Jared Weiss (5546900), Christopher Dakhil (5546876), Alexandra Sanford (5546849), Katayoun Amiri (5546870), David A. Smith (2577271)   +16 more
core   +1 more source

ALDH2 Suppresses Ferroptosis and Promotes Bortezomib Resistance in Multiple Myeloma Through the KEAP1‐NRF2 Feedback Loop

Advanced Science, EarlyView.
ALDH2, which is overexpressed in multiple myeloma, competitively binds KEAP1 to stabilize NRF2 by blocking its ubiquitin‐proteasomal degradation. Stabilized NRF2 translocates into the nucleus to upregulate the expression of GPX4. In parallel, NRF2 binds to the ALDH2 promoter to regulate its transcription, forming a positive feedback loop that represses
Ruonan Shao, Chengcheng Liu, Xinpei Deng, Jindong Xie, Wenjian Liu, Bin Yang, Lingrui Liu, Cailu Song, Lei Li, Hua Wang, Hailin Tang   +10 more
wiley   +1 more source

pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy

International Journal of Nanomedicine, 2012
Jae-Yoon Shin,1,* Yoosoo Yang,1,* Paul Heo,1 Ji-Chun Lee,1 ByoungJae Kong,1 Jae Youl Cho,1 Keejung Yoon,1 Cheol-Su Shin,2 Jin-Ho Seo,3 Sung-Gun Kim,4 Dae-Hyuk Kweon11Department of Genetic Engineering, College of Biotechnology and Bioengineering, and ...
Shin JY, Yang Y, Heo P, Lee JC, Kong BJ, Cho JY, Yoon K, Shin CS, Seo JH, Kim SG, Kweon DH   +10 more
doaj  

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +1 more source

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

, 2013
Carlo Lazzaro,1 Roberto Bordonaro,2 Francesco Cognetti,3 Alessandra Fabi,3 Sabino De Placido,4 Grazia Arpino,4 Paolo Marchetti,5 Andrea Botticelli,5 Paolo Pronzato,6 Elisa Martelli7 1Studio di Economia Sanitaria, Milan, Italy; 2Public Hospital Trust ...
Bordonaro R, Cognetti F, Marchetti P, Martelli E, De Placido S, Lazzaro C, Pronzato P, Fabi A, Arpino G, Botticelli A   +9 more
core  

Chemical Structures of Paclitaxel, Docetaxel, and Paclitaxel Derivatives.

, 2015
Chemical Structures of Paclitaxel, Docetaxel, and Paclitaxel Derivatives.
Richard F. Ludueña (751489), Sambasivarao Damaraju (102523), Ahmed T. Ayoub (747972), Carol E. Cass (102519), Mariusz Klobukowski (747973), Jack A. Tuszynski (160860), Marc St. George (318231), Philip Winter (291799), Asok Banerjee (751487), Cassandra D. M. Churchill (751488)   +9 more
core   +1 more source